Febuxostat in Gout: Serum Urate Response in Uric Acid Overproducers and Underexcretors D.S. Goldfarb, P.A. MacDonald, B. Hunt, L. Gunawardhana ........................................ 1385
Longterm Therapeutic Response to Minacapream Treatment for FM: A European 1-Year Extension Study Following a 3-Month Study J.C. Branco, P. Cherin, A. Montagne, A. Bourroubi, on behalf of the Multinational Coordinator Study Group .................. 1403

Pediatric Rheumatology
Heterotopic Ossification of the TMJ in JIA S. Ringold, M. Thapa, E.A. Shaw, C.A. Wallace .............. 1423
MBL Expression Genotype in Pediatric-onset SLE: Associations with Susceptibility to Renal Disease and Protection Against Infections Y-C. Tsai, K-W. Yeh, T-C. Yao, Y-L. Huang, M-L. Kuo, J-L. Huang .................. 1429
Development of IBD in Patients with JIA Treated with Etanercept T.D. van Dijken, S.J. Vastert, V.M. Gerloni, et al .... 1441

Images in Rheumatology
Fluorescence Optical Imaging of Juvenile Arthritis S.G. Werner, H-E. Langer, G. Horneff ........................................ 1447
OMERACT 10 10th International Consensus Conference on Outcome Measures in Rheumatology Kota Kinabalu, Borneo - May 4-8, 2010 Introduction ........................................ 1448
Tophus Measurement as an Outcome Measure for Clinical Trials of Chronic Gout: Progress and Research Priorities N. Dalbeth, F.M. McQueen, J.A. Singh, et al ................. 1458
Serum Urate in Chronic Gout — Will It Be the First Validated Soluble Biomarker in Rheumatology? L.K. Stamp, P.P. Khanna, N. Dalbeth, et al .......................................... 1462

Toward Development of a FM Responder Index and Disease Activity Score: OMERACT Module Update P.J. Mease, D.J. Clauw, R. Christensen, et al. and the OMERACT Fibromyalgia Working Group ........................................ 1487
Endorsement of Definitions of Disease Activity States and Improvement Scores for the AS Disease Activity Score: Results from OMERACT 10 P.M.M.C. Machado, R.B.M. Landewé, D.M. van der Heijde .......................... 1502
Developing Disease Activity and Response Criteria in CTD-related ILD L.A. Saketkoo, E.L. Matteson, K.K. Brown, J.R. Seibold, V. Strand; for the Connective Tissue Disease-related Interstitial Lung Disease Special Interest Group ........................................ 1514

Correspondence
Where in the World is Oral Triamcinolone? L. Roger ............ 1519
Reply R. Alten ........................................ 1519
Lupus Related Longitudinal Myelitis D.M. Wingerchuk, B.G. Wechsner ........................................ 1520
Reply P. Zotos ........................................ 1521
Who Discovered the ESR? A. Grzybowski, J.J. Sak ............. 1521
Reply E.L. Matteson, C.S. Crowson ............................ 1523

Letters
Acute Presentation of Tophaceous Myelopathy E. Levin, K. Hurth, R. Joshi, R. Brasington ......................... 1525
AS Refractory to TNF Blockade Responds to Tocilizumab J-D. Cohen, R. Ferreira, C. Jorgensen ........................................ 1527
Positive C-ANCA with PR3 Specificity Glomerulonephritis in a Patient with Subacute Bacterial Endocarditis M. Uhl, I.A. McCormick, J.T. Kelsall ......................... 1528
Primary Aldosteronism Simulating Polymyositis Y-C. Tang, S-K. Wang, W-L. Yuan ........................................ 1529

Corrections
Intraarticular Botulinum Toxin A for Refractory Painful Total Knee Arthroplasty: A Randomized Controlled Trial J.A. Singh, M.L. Mahowald, S. Noorbavochi ........................................ 1534
Meetings in Rheumatology